keyword
MENU ▼
Read by QxMD icon Read
search

Vegf eye

keyword
https://www.readbyqxmd.com/read/28107458/neuropilin-1-involvement-in-choroidal-and-retinal-neovascularisation
#1
Patricia Fernández-Robredo, Senthil Selvam, Michael B Powner, Dawn A Sim, Marcus Fruttiger
PURPOSE: Inhibiting VEGF is the gold standard treatment for neovascular age-related macular degeneration (AMD). It is also effective in preventing retinal oedema and neovascularisation (NV) in diabetic retinopathy (DR) and retinal vein occlusions (RVO). Neuropilin 1 (Nrp1) is a co-receptor for VEGF and many other growth factors, and therefore a possible alternative drug target in intra ocular neovascular disease. Here we assessed choroidal and retinal NV in an inducible, endothelial specific knock out model for Nrp1...
2017: PloS One
https://www.readbyqxmd.com/read/28106889/the-incidence-and-risk-factors-for-the-development-of-vitreomacular-interface-abnormality-in-diabetic-macular-edema-treated-with-intravitreal-injection-of-anti-vegf
#2
C-K Chang, C-K Cheng, C-H Peng
PurposeTo report the incidence and associated factors for the development of vitreomacular interface abnormality (VMIA) in patients with diabetic macular edema (DME) who received intravitreal injection (IVI) of anti-VEGF (Bevacizumab and Ranibizumab) treatment.MethodsA retrospective observational study. Patients with DME followed at least 6 months were reviewed. Baseline best-corrected visual acuity (BCVA), central retinal thickness (CRT) and final BCVA, CRT in eyes with and without VMIA were compared. Multiple logistic regression was also used to investigate the risk factors of VMIA formation in patients with DME treated by anti-VEGF...
January 20, 2017: Eye
https://www.readbyqxmd.com/read/28105123/effect-of-anti-vegf-drugs-combined-with-photodynamic-therapy-in-the-treatment-of-age-related-macular-degeneration
#3
Yi Dong, Guangming Wan, Panshi Yan, Yue Chen, Wenzhan Wang, Guanghua Peng
We analyzed the effects of anti-vascular endothelial growth factor (VEGF) drugs combined with photodynamic therapy (PDT) in the treatment of age-related macular degeneration (AMD). Ninety-six cases (192 eyes) of AMD were included in this study and randomly divided into the observation group and control group (n=48 cases per group). The control group was administered the treatment of Lucentis intravitreal injection alone and the observation group was administered Lucentis combined with PDT. The therapeutic effects were compared...
December 2016: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28103602/intraocular-cytokines-and-their-correlations-with-clinical-parameters-in-patients-with-myopic-choroidal-neovascularization
#4
Andrey G Shchuko, Natalia V Zaitseva, Tatyana N Yurieva, Elena R Chernykh, Isay M Mikhalevich, Ekaterina Y Shevela, Alina V Grigorieva
PURPOSE: To study cytokine levels in aqueous humor of patients with myopic choroidal neovascularization (mCNV), their correlations with each other and ocular parameters. METHODS: Ophthalmological examination and immunological study of aqueous humor with cytokine levels measurement (Bio-Plex™ Human Cytokine 27-Plex panel; Bio-Rad Laboratories, USA) were performed in 19 patients (19 eyes) with ranibizumab-treated mCNV and compared to 15 patients (15 eyes) with myopia without CNV...
January 20, 2017: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/28100839/tyrosine-kinase-blocking-collagen-iv-derived-peptide-suppresses-ocular-neovascularization-and-vascular-leakage
#5
Raquel Lima E Silva, Yogita Kanan, Adam C Mirando, Jayoung Kim, Ron B Shmueli, Valeria E Lorenc, Seth D Fortmann, Jason Sciamanna, Niranjan B Pandey, Jordan J Green, Aleksander S Popel, Peter A Campochiaro
Vascular endothelial growth factor (VEGF)-neutralizing proteins provide benefit in several retinal and choroidal vascular diseases, but some patients still experience suboptimal outcomes, and the need for frequent intraocular injections is a barrier to good outcomes. A mimetic peptide derived from collagen IV, AXT107, suppressed subretinal neovascularization (NV) in two mouse models predictive of effects in neovascular age-related macular degeneration (NVAMD) and inhibited retinal NV in a model predictive of effects in ischemic retinopathies...
January 18, 2017: Science Translational Medicine
https://www.readbyqxmd.com/read/28098727/persistent-overproduction-of-intraocular-vascular-endothelial-growth-factor-as-a-cause-of-late-vitreous-hemorrhage-after-vitrectomy-for-proliferative-diabetic-retinopathy
#6
Yoshihiro Wakabayashi, Yoshihiko Usui, Kinya Tsubota, Shunichiro Ueda, Kazuhiko Umazume, Daisuke Muramatsu, Hiroshi Goto
PURPOSE: The purpose of this study was to investigate whether vitreous levels of vascular endothelial growth factor (VEGF) predict late vitreous hemorrhage (VH) after vitrectomy for proliferative diabetic retinopathy, and how VEGF level changes in patients with postoperative late VH. METHODS: Eighty-five eyes of 68 patients with proliferative diabetic retinopathy who underwent vitrectomy were analyzed retrospectively. Vitreous samples were collected from eyes undergoing primary vitrectomy and from eyes with late VH undergoing second vitrectomy...
January 16, 2017: Retina
https://www.readbyqxmd.com/read/28088487/adenosine-receptors-and-caffeine-in-retinopathy-of-prematurity
#7
REVIEW
Jiang-Fan Chen, Shuya Zhang, Rong Zhou, Zhenlang Lin, Xiaohong Cai, Jing Lin, Yuqin Huo, Xiaoling Liu
Retinopathy of prematurity (ROP) is a major cause of childhood blindness in the world and is caused by oxygen-induced damage to the developing retinal vasculature, resulting in hyperoxia-induced vaso-obliteration and subsequent delayed retinal vascularization and hypoxia-induced pathological neovascularization driven by vascular endothelial growth factor (VEGF) signaling pathway in retina. Current anti-VEGF therapy has shown some effective in a clinical trial, but is associated with the unintended effects on delayed eye growth and retinal vasculature development of preterm infants...
January 11, 2017: Molecular Aspects of Medicine
https://www.readbyqxmd.com/read/28077879/determinants-of-visual-acuity-outcomes-in-eyes-with-neovascular-amd-treated-with-anti-vegf-agents-an-instrumental-variable-analysis-of-the-aura-study
#8
F G Holz, R Tadayoni, S Beatty, A R Berger, M G Cereda, P Hykin, G Staurenghi, K Wittrup-Jensen, J Nilsson, K Kim, S Sivaprasad
No abstract text is available yet for this article.
January 2017: Eye
https://www.readbyqxmd.com/read/28060586/evidence-based-treatment-of-diabetic-macular-edema
#9
Rasha Barham, Hala El Rami, Jennifer K Sun, Paolo S Silva
Diabetes mellitus is a chronic disease that affects 415 million people worldwide. Despite treatment advances, diabetic eye disease remains a leading cause of vision loss worldwide. Diabetic macular edema (DME) is a common cause of vision loss in diabetic patients. The pathophysiology is complex and involves multiple pathways that ultimately lead to central retinal thickening and, if untreated, visual loss. First-line treatment of DME has evolved from focal/grid laser established by the Early Treatment of Diabetic Retinopathy Study (ETDRS) to intravitreous pharmacologic therapy...
2017: Seminars in Ophthalmology
https://www.readbyqxmd.com/read/28053502/neovascular-age-related-macular-degeneration-without-drusen-in-the-fellow-eye-clinical-spectrum-and-therapeutic-outcome
#10
Wing H Chung, Elon H C van Dijk, Danial Mohabati, Greet Dijkman, Suzanne Yzer, Eiko K de Jong, Sascha Fauser, Reinier O Schlingemann, Carel B Hoyng, Camiel J F Boon
PURPOSE: To investigate the clinical characteristics and therapeutic outcome of patients with neovascular age-related macular degeneration (nAMD) in 1 eye, without drusen in the fellow eye. PATIENTS AND METHODS: Medical records of 381 patients were analyzed to identify the cases. The main outcomes included Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) and change in central retinal thickness (CRT). These parameters were reviewed at baseline, first follow-up visit, and after 6, 12, and 24 months...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28048946/intravitreal-anti-vascular-endothelial-growth-factor-drugs-for-retinal-angiomatous-proliferation-in-real-life-practice
#11
Maurizio Battaglia Parodi, Simone Donati, Francesco Semeraro, Paola Danzi, Ugo Introini, Francesco Viola, Ferdinando Bottoni, Vincenzo Pucci, Andrea Musig, Alfredo Pece, Claudio Azzolini
PURPOSE: To describe the outcomes of intravitreal anti-vascular endothelial growth factor (VEGF) in the treatment of retinal angiomatous proliferation (RAP) in real-life practice in 7 Italian centers under the Progetto Luce initiative. METHODS: Clinical data of 95 eyes of 95 patients affected by RAP, regularly followed up and treated with either intravitreal ranibizumab or bevacizumab over 12 months, were examined. After a loading phase of 3 consecutive injections, retreatments were administered following a pro-re-nata regimen on the basis of the persistence or the recurrence of subretinal/intraretinal fluid on optical coherence tomography, or leakage on fluorescein angiography...
January 3, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28031700/long-term-results-of-combination-therapy-using-anti-vegf-agents-and-dexamethasone-intravitreal-implant-for-retinal-vein-occlusion-an-investigational-case-series
#12
Michael A Singer, Michael E Jansen, Lyndon Tyler, Paul Woods, Faisal Ansari, Udit Jain, Joshua Singer, Darren Bell, Chelsey Krambeer
BACKGROUND: One limitation of anti-VEGF therapy is the need for monthly retreatment to maintain efficacy. The purpose of this study was to determine the duration of effect in eyes with macular edema (ME) secondary to branch or central retinal vein occlusion (BRVO or CRVO) treated with anti-VEGF therapy plus sustained-release dexamethasone (DEX implant; Ozurdex). MATERIALS AND METHODS: This open-label, interventional case series included 62 eyes with ME due to RVO, central foveal thickness (CFT) >300 μm, and best-corrected visual acuity (BCVA) of 20/40 or worse...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28028001/pharmacokinetic-aspects-of-retinal-drug-delivery
#13
REVIEW
Eva M Del Amo, Anna-Kaisa Rimpelä, Emma Heikkinen, Otto K Kari, Eva Ramsay, Tatu Lajunen, Mechthild Schmitt, Laura Pelkonen, Madhushree Bhattacharya, Dominique Richardson, Astrid Subrizi, Tiina Turunen, Mika Reinisalo, Jaakko Itkonen, Elisa Toropainen, Marco Casteleijn, Heidi Kidron, Maxim Antopolsky, Kati-Sisko Vellonen, Marika Ruponen, Arto Urtti
Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical...
December 24, 2016: Progress in Retinal and Eye Research
https://www.readbyqxmd.com/read/28003779/pneumatic-displacement-of-submacular-haemorrhage
#14
Ehab Abdelkader, Kay P Yip, Kurt Spiteri Cornish
PURPOSE: To evaluate the outcomes of pneumatic displacement of submacular hemorrhage secondary to choroidal neovascular membrane (CNV) (n = 9) and retinal arterial macroaneurysm (RAM) (n = 3). METHODS: This is a retrospective case series study of 12 eyes from 12 patients in Aberdeen Royal Infirmary, Aberdeen, UK. The mean duration of visual loss was 10.8 ± 4.11 days. All cases received intravitreal injection of expansile gas within 24 h of presentation (C3F8 in 11 cases and SF6 in one case) and postured face down for five days...
October 2016: Saudi Journal of Ophthalmology: Official Journal of the Saudi Ophthalmological Society
https://www.readbyqxmd.com/read/28002284/outcomes-of-anti-vegf-therapy-in-choroidal-neovascularization-after-macular-surgery
#15
Duc Anh Hua, Antonio M Casella, Maria H Berrocal, Dennis Han, Rayan A Alshareef, Hugo Quiroz-Mercado, J Fernando Arevalo, Jay Chhablani
PURPOSE: To report treatment outcomes of anti-vascular endothelial growth factor (VEGF) therapy in choroidal neovascularization (CNV) presenting after macular surgery. METHODS: Retrospective analysis of 7 eyes of 7 patients, who were diagnosed to have CNV after macular surgery and were treated with anti-vascular endothelial growth factor therapy. Collected data included demographic details; history of present illness; surgical procedure; and clinical examination including visual acuity at presentation and follow-up with imaging and management...
December 20, 2016: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/27994436/role-of-endogenous-insulin-gene-enhancer-protein-isl-1-in-angiogenesis
#16
Si-Qi Xiong, Hai-Bo Jiang, Yan-Xiu Li, Hai-Bo Li, Hui-Zhuo Xu, Zhen-Kai Wu, Wei Zheng, Xiao-Bo Xia
OBJECTIVE: To elucidate the role of insulin gene enhancer protein ISL-1 (Islet-1) in angiogenesis and regulation of vascular endothelial growth factor (VEGF) expression in vitro and in vivo. METHODS: siRNA targeting Islet-1 was transfected to human umbilical vein endothelial cell lines (HUVECs). The expression of Islet-1 and VEGF in the cultured cells was measured using real-time PCR and immunoblotting. 3-[4,5-dimethylthiazol-2-yl]-2,5- diphenyltetrazolium bromide; thiazolyl blue (MTT) assay was used to analyze the proliferation of HUVECs affected by Islet-1...
2016: Molecular Vision
https://www.readbyqxmd.com/read/27994435/pkr-promotes-choroidal-neovascularization-via-upregulating-the-pi3k-akt-signaling-pathway-in-vegf-expression
#17
Manhui Zhu, Xiaojuan Liu, Shengcun Wang, Jin Miao, Liucheng Wu, Xiaowei Yang, Ying Wang, Lihua Kang, Wendie Li, Chen Cui, Hui Chen, Aimin Sang
PURPOSE: The aim of this study was to investigate the functions of dsRNA-activated protein kinase (PKR) in choroidal neovascularization (CNV) and related signaling pathways in the production of vascular endothelial growth factor (VEGF). METHODS: A chemical hypoxia model of in vitro RF/6A cells, a rhesus choroid-retinal endothelial cell line, was established by adding cobalt chloride (CoCl2) to the culture medium. PKR, phosphophosphatidylinositol 3-kinase (p-PI3K), phosphoprotein kinase B (p-Akt), and VEGF protein levels in RF/6A cells were detected with western blotting...
2016: Molecular Vision
https://www.readbyqxmd.com/read/27993591/histopathologic-characterization-of-the-expression-of-vascular-endothelial-growth-factor-in-a-case-of-retinopathy-of-prematurity-treated-with-ranibizumab
#18
Maria P Fernandez, Audina M Berrocal, Tyler C Goff, Mark P Ghassibi, Clio A Harper, Eva Chou, Simon K Michael, Justin Hellman, Sander R Dubovy
PURPOSE: To characterize the expression of Vascular Endothelial Growth Factor (VEGF) in a patient with Retinopathy of prematurity (ROP) treated with Ranibizumab (Case 1) and compare it to a case of ROP without treatment (Case 2), a case of a premature baby without ROP (Case 3) and a case of a baby without history of ROP or prematurity (Case 4). DESIGN: Observational case series METHODS: The eyes of the deceased babies were removed post mortem and were sent to the Florida Lions Ocular Pathology Laboratory where they were processed...
December 16, 2016: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/27991837/vision-preservation-in-eyes-of-polypoidal-choroidal-vasculopathy-with-low-dose-intravitreal-triamcinolone-acetonide
#19
I-Chia Liang, Yi-Ru Lin, Hsiang-Wen Chien, Kwan-Rong Liu
PURPOSE: To evaluate the efficacy and adverse effects of using low-dose intravitreal triamcinolone acetonide (IVTA) to preserve vision in polypoidal choroidal vasculopathy (PCV) eyes. METHODS: This retrospective chart review study examined 8 eyes of 7 PCV patients, for whom verteporfin photodynamic therapy (vPDT) or antivascular endothelial growth factor (VEGF) therapy was not affordable/available and also with intolerable risk because of underlying cardiovascular and/or cerebrovascular ischemia...
January 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/27990354/effect-of-trapping-vascular-endothelial-growth-factor-a-in-a-murine-model-of-dry-eye-with-inflammatory-neovascularization
#20
Jin Woo Kwon, Jin A Choi, Eun Young Shin, Tae Yoon La, Dong Hyun Jee, Yeon Woong Chung, Yang Kyung Cho
AIM: To evaluate whether trapping vascular endothelial growth factor A (VEGF-A) would suppress angiogenesis and inflammation in dry eye corneas in a murine corneal suture model. METHODS: We established two groups of animals, one with non-dry eyes and the other with induced dry eyes. In both groups, a corneal suture model was used to induce inflammation and neovascularization. Each of two groups was again divided into three subgroups according to the treatment; subgroup I (aflibercept), subgroup II (dexamethasone) and subgroup III (phosphate buffered saline, PBS)...
2016: International Journal of Ophthalmology
keyword
keyword
4979
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"